Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

HDM1002

Stage Phase 3Stale

Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co

Route oral

Class GLP-1 RA

Mechanism oral GLP-1 receptor agonist

Sources

registry, as of 2025-03-19Stale

https://clinicaltrials.gov/study/NCT06885021

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 780. Conditions Overweight and Obesity. A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

ClinicalTrials.gov NCT06885021 protocol and results modules

registry, as of 2024-07-15Stale

https://clinicaltrials.gov/study/NCT06500299

Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 180. Conditions Overweight and Obesity. It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.

ClinicalTrials.gov NCT06500299 protocol and results modules

registry, as of 2026-01-09Stale

https://clinicaltrials.gov/study/NCT07331389

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin. Overall status RECRUITING. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 111. Conditions Overweight Subject; Healthy Subjects. The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and

ClinicalTrials.gov NCT07331389 protocol and results modules

registry, as of 2024-07-25Stale

https://clinicaltrials.gov/study/NCT06520540

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects. Overall status UNKNOWN. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 72. Conditions Glucagon-Like Peptide-1 Receptor Agonists. • To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.

ClinicalTrials.gov NCT06520540 protocol and results modules

registry, as of 2024-09-23Stale

https://clinicaltrials.gov/study/NCT06601517

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.. Overall status UNKNOWN. Phases PHASE1. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 30. Conditions Healthy Adult Subject; Overweight Subject. The purpose of this study is to characterize the effect of HDM1002 on the PK of single dose of repaglinide, atorvastatin, digoxin and rosuvastatin in healthy adult subjects. The safety and tolerability of HDM1002 with repaglinide, atorvastatin, digoxin and rosuvastatin when given

ClinicalTrials.gov NCT06601517 protocol and results modules

publication, as of 2025-09-04Stale

https://pubmed.ncbi.nlm.nih.gov/40662378/

First-in-human study of HDM1002, a GLP-1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers. To evaluate the safety, tolerability, pharmacokinetics (PK) and

PMID 40662378

Studies

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

Registry NCT06885021

Phase Phase 3

Status Not yet recruiting

Enrollment 780

Start 2025-03-28

Primary completion 2026-05-30

Study completion 2026-06-30

Catalyst Primary completion. 2026-05-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HDM1002 tablets 200mg once daily

Dose 200mg

Regimen once daily

Weeks 52

Comparator placebo

Population Overweight and Obesity

HDM1002 tablets 400mg once daily

Dose 400mg

Regimen once daily

Weeks 52

Comparator placebo

Population Overweight and Obesity

Placebo

Regimen once daily

Weeks 52

Population Overweight and Obesity

Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Registry NCT06500299

Phase Phase 2

Enrollment 180

Start 2024-07-15

Primary completion 2024-10-30

Study completion 2024-11-30

HDM1002 100mg BID

Dose 100mg

Regimen twice daily

Weeks 12

Comparator placebo

Population Overweight and Obesity

HDM1002 200mg BID

Dose 200mg

Regimen twice daily

Weeks 12

Comparator placebo

Population Overweight and Obesity

HDM1002 400mg QD

Dose 400mg

Regimen once daily

Weeks 12

Comparator placebo

Population Overweight and Obesity

placebo

Regimen once daily

Weeks 12

Population Overweight and Obesity

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Registry NCT07331389

Phase Phase 1

Status Recruiting

Enrollment 111

Start 2025-09-24

Primary completion 2026-01-12

Study completion 2026-06-13

Catalyst Primary completion. 2026-01-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

experimental arm

Population Overweight Subject; Healthy Subjects

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

Registry NCT06520540

Phase Phase 1

Enrollment 72

Start 2024-07-28

Primary completion 2024-11-30

Study completion 2024-12-30

HDM1002 100 mg

Dose 100 mg

Regimen once daily

Weeks 12

Comparator placebo

Population Glucagon-Like Peptide-1 Receptor Agonists

HDM1002 200 mg

Dose 200 mg

Regimen once daily

Weeks 12

Comparator placebo

Population Glucagon-Like Peptide-1 Receptor Agonists

HDM1002 400 mg

Dose 400 mg

Regimen once daily

Weeks 12

Comparator placebo

Population Glucagon-Like Peptide-1 Receptor Agonists

Placebo

Regimen once daily

Weeks 12

Population Glucagon-Like Peptide-1 Receptor Agonists

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.

Registry NCT06601517

Phase Phase 1

Enrollment 30

HDM1002 with Repaglinide, Atorvastatin, Digoxin and Rosuvastatin

Regimen once daily

Population Healthy Adult Subject; Overweight Subject